Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)

Christel Fontaine,Vincent Renard,Heidi Van den Bulk,Peter Vuylsteke,Philip Glorieux,C. Dopchie,Lore Decoster,Leen Vanacker,Evandro de Azambuja,Jacques De Grève,Ahmad Awada,Hans Wildiers

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)

2019

Christel Fontaine
Vincent Renard
Heidi Van den Bulk
Peter Vuylsteke
Philip Glorieux
C. Dopchie
Lore Decoster
Leen Vanacker
Evandro de Azambuja
Jacques De Grève
Ahmad Awada
Hans Wildiers

Aim To evaluate the pCR rate and toxicity of the addition of weekly carboplatin (Cp) to paclitaxel (wP) and dose-dense (dd) epirubicin/cyclophosphamide (EC) in an open-label phase II study in TNBC patients.

Keywords:

Taxane
Breast cancer
Triple-negative breast cancer
Anthracycline
Epirubicin
Regimen
Paclitaxel
Carboplatin
Medicine
Oncology
Internal medicine
Phases of clinical research
Neutropenia
Febrile neutropenia
Tolerability

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations